Matula, Z.; Gönczi, M.; Bekő, G.; Kádár, B.; Ajzner, É.; Uher, F.; Vályi-Nagy, I.
Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. Vaccines 2022, 10, 539.
https://doi.org/10.3390/vaccines10040539
AMA Style
Matula Z, Gönczi M, Bekő G, Kádár B, Ajzner É, Uher F, Vályi-Nagy I.
Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. Vaccines. 2022; 10(4):539.
https://doi.org/10.3390/vaccines10040539
Chicago/Turabian Style
Matula, Zsolt, Márton Gönczi, Gabriella Bekő, Béla Kádár, Éva Ajzner, Ferenc Uher, and István Vályi-Nagy.
2022. "Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy" Vaccines 10, no. 4: 539.
https://doi.org/10.3390/vaccines10040539
APA Style
Matula, Z., Gönczi, M., Bekő, G., Kádár, B., Ajzner, É., Uher, F., & Vályi-Nagy, I.
(2022). Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. Vaccines, 10(4), 539.
https://doi.org/10.3390/vaccines10040539
